Published in Neurogastroenterol Motil on February 24, 2010
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol (2012) 0.93
A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol (2012) 0.90
Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil (2012) 0.87
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology (2013) 0.86
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol (2015) 0.80
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol (2015) 0.78
Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology (2016) 0.78
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther (2015) 0.76
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci (2004) 2.29
The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res (2009) 2.11
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil (2009) 1.59
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology (2005) 1.47
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut (2008) 1.47
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol (1996) 1.40
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol (2004) 1.33
Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol (1998) 1.31
A molecular basis of analgesic tolerance to cannabinoids. J Neurosci (2007) 1.28
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med (Berl) (2005) 1.25
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol (2007) 1.17
Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One (2009) 1.16
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol (1999) 1.13
Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.13
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol (2008) 1.11
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol (2000) 1.07
The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J (2002) 1.06
The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol (2004) 1.06
Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol (1998) 1.05
Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil (2009) 1.05
Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil (2006) 1.00
Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol (1997) 0.98
The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol (2001) 0.98
Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol (2002) 0.98
Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol (2006) 0.97
Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am J Physiol Gastrointest Liver Physiol (2008) 0.97
Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res (2007) 0.96
Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol (2003) 0.96
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol (2008) 0.95
Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis (2002) 0.94
Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol (2006) 0.93
Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil (2009) 0.91
Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol (1998) 0.90
Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci (2001) 0.90
Regional differences in gastrointestinal motility disturbances during acute necrotising pancreatitis. Neurogastroenterol Motil (2005) 0.90
Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil (2007) 0.90
Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil (2008) 0.90
Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol (2000) 0.90
Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol (2007) 0.85
Kinin-induced anion-dependent secretion in porcine ileum: characterization and involvement of opioid- and cannabinoid-sensitive enteric neural circuits. J Pharmacol Exp Ther (2003) 0.82
The central and peripheral effects of delta-9-tetrahydrocannabinol on gastrointestinal transit in mice. NIDA Res Monogr (1986) 0.76
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci (1999) 4.65
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 4.39
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Modulation of Ca2+ channels by G-protein beta gamma subunits. Nature (1996) 3.79
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med (2001) 3.17
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci (1999) 2.92
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology (1998) 2.46
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol (1990) 2.36
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest (1996) 2.31
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 2.15
Reconstitution of muscarinic modulation of the KCNQ2/KCNQ3 K(+) channels that underlie the neuronal M current. J Neurosci (2000) 2.15
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1993) 2.10
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol (1997) 2.05
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 2.03
Recurrent aphthous ulcers today: a review of the growing knowledge. Int J Oral Maxillofac Surg (2004) 1.89
Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol (1999) 1.83
Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem (1999) 1.82
Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci (1999) 1.80
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J (1997) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience (1999) 1.77
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord (2003) 1.74
An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol (1990) 1.71
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 1.63
Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci U S A (1998) 1.61
Failed coronary stent deployment. Am Heart J (1998) 1.60
Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci (2001) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost (1996) 1.53
The nucleotide sequence of Saccharomyces cerevisiae chromosome V. Nature (1997) 1.53
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
Indiscriminate loss of myenteric neurones in the TNBS-inflamed guinea-pig distal colon. Neurogastroenterol Motil (2005) 1.51
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Expression pattern of the Kallmann syndrome gene in the olfactory system suggests a role in neuronal targeting. Nat Genet (1993) 1.43
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci (1997) 1.42
Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood (1989) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Role of Porphyromonas gingivalis protease activity in colonization of oral surfaces. Infect Immun (1996) 1.41
Structure and orientation of the pore-forming peptide, melittin, in lipid bilayers. J Mol Biol (1994) 1.39
Towards early defibrillation--a nurse training programme in the use of automated external defibrillators. Resuscitation (1995) 1.38
Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience (2002) 1.37
Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature (2000) 1.36
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) (2001) 1.36
CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience (2005) 1.35
Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut (1999) 1.35
Leishmania donovani: oral efficacy and toxicity of formycin B in the infected hamster. Exp Parasitol (1983) 1.34
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Sensory substance P innervation of the stomach and pancreas. Demonstration of capsaicin-sensitive sensory neurons in the rat by combined immunohistochemistry and retrograde tracing. Gastroenterology (1984) 1.29
Genotypic diversity of mutans streptococci in Brazilian nursery children suggests horizontal transmission. J Clin Microbiol (2001) 1.29
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol (2007) 1.29
Role of Arg-gingipain A in virulence of Porphyromonas gingivalis. Infect Immun (1998) 1.29
Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus. Infect Immun (1983) 1.27
Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther (1999) 1.26
MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene (2010) 1.25
GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience (2000) 1.25
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
The orthologous human and murine semaphorin 6A-1 proteins (SEMA6A-1/Sema6A-1) bind to the enabled/vasodilator-stimulated phosphoprotein-like protein (EVL) via a novel carboxyl-terminal zyxin-like domain. J Biol Chem (2000) 1.24
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy. Leuk Lymphoma (2002) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Plasticity of the enteric nervous system during intestinal inflammation. Neurogastroenterol Motil (2005) 1.23
Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology (1992) 1.23
Changes in colonic motility and the electrophysiological properties of myenteric neurons persist following recovery from trinitrobenzene sulfonic acid colitis in the guinea pig. Neurogastroenterol Motil (2007) 1.23
Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol (2005) 1.22
Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest (2006) 1.22
Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil (2009) 1.21
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol (2011) 1.21
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol (1997) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Comparison of ceftizoxime and penicillin for the treatment of uncomplicated gonorrhoea. J Antimicrob Chemother (1982) 1.18
Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience (2005) 1.18
Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil (2005) 1.17
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol (1995) 1.17
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci (1999) 1.16
Enteric glia. Neurogastroenterol Motil (2004) 1.16